An RNA platform successfully predicted fetal growth restriction within the second trimester of pregnancy, independent of other risk factors, according to a presentation at The Pregnancy Meeting.

Key cells in the brain, neurons, form networks by exchanging signals, enabling the brain to learn and adapt at incredible ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

Meet the woman leading vaccine innovation in Senegal to fight Rift Valley fever and empower Africa’s next generation of ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

In 2025, the AI landscape is undergoing a transformative shift, expanding into two critical new layers: the application layer ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

For 2025, Lonza expects strong performance in its CDMO business with CER sales growth approaching 20% and CORE EBITDA margin approaching 30%. Excluding Vacaville, which is expected to contribute ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...